Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect

We expect investors to focus on Altimmune’s ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results.Since ALT lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for the bottom line is pegged...